Objective: The aim of this study was to find out whether upper extremity is relatively preserved and to what extent it is affected by Primary Progressive Multiple Sclerosis (PPMS) through the evaluation and comparison of upper extremity fine motor skills and walking ability in PPMS and Secodary Progressive Multiple Sclerosis (SPMS) patients with Expanded Disability Status Scale (EDSS) score of 4 and above. Material and Methods: A total of 65 progressive Multiple Sclerosis (MS) patients admitted to the Neurology Outpatient Clinic of Yüzüncü Yıl University Faculty of Medicine between January and December 2017 with EDSS scores ranging from 4.0 to 8.5 were included in our study. Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT) and Timed 25-Foot Walk (T25FW) Test were applied to the patients. Results: 9-Hole Peg Test right hand score of PPMS patients with EDSS score between 5.1 and 6.0 was 32.89±7.42 sec, whereas in SPMS patients within the same score range, it was 56.15±54.57 sec (p>0.05). 9- Hole Peg Test left hand score was found as 39.64±16.71 sec in PPMS patients and 47.51±27.32 sec (p>0.05) in SPMS patients. 9-Hole Peg Test mean score was 36.25±11.83 sec in PPMS patients and 51.83±38.18 sec in SPMS patients (p>0.05). The T25FW test was calculated only for 39 patients who were able to perform all tests. In 14 patients with PPMS, the first-stage T25FW test score was 35.62±22.2 sec, the second-stage score was 36.21±24.73 sec, and the mean T25FW test score was 35.92±22.81 sec. In 25 of SPMS patients, the first-stage T25FW test result was 36,12±32,84 sec, the second-stage T25FW test result was 32,77±26,11 sec, and the mean T25FW test result was 34,4±28,75 sec. Conclusion: In PPMS and SPMS patients with EDSS score of 5.1-6.0, the mean EDSS scores were observed to be closer to each other, and in PPMS patients in this group, the upper extremity function was relatively better, although not statistically significant. No significant difference was found between the groups in terms of lower extremity function.
Keywords: Upper and lower extremity function in patients with progressive MS; 9-Hole Peg test (9-HPT) and Timed 25-Foot Walk (T25FW)
Amaç: Çalışmamızın amacı Primer Progresif Multipl Skleroz (PPMS) ve Sekonder Progresif Multipl Skleroz (SPMS) hastalarında Genişletilmiş Özürlülük Durum Ölçeği (EDSS) puanı 4 ve üzerinde olan hasta grubunda üst ekstremite ince motor becerisini ve yürüme becerisini değerlendirip birbiri ile kıyaslayarak, PPMS'de üst ekstremitenin göreceli olarak korunup korunmadığını ve ne derecede etkilendiğini göstermektir. Gereç ve Yöntemler: Çalışmamıza 2017 yılı Ocak-Aralık ayları arasında Yüzüncü Yıl Üniversitesi Tıp Fakültesi Nöroloji polikliniğine başvuran EDSS 4,0-8,5 arasında olan toplam 65 progresif Multipl Skleroz (MS) hastası dahil edilmiştir. Hastalara Expanded Disability Status Scala(EDSS, Genişletilmiş Özürlülük Durum Ölçeği), 9-Hole PEG testi (9-HPT, Dokuz delikli çubuk testi) ve Timed 25 Food Walk (25 Adımlı Yürüme Testi,T25FW) testleri uygulandı. Bulgular: Genişletilmiş Özürlülük Durum Ölçeği 5.1-6.0 arasındaki hastalarda sağ el testi PPMS hastalarında 32,89±7,42 sn, SPMS hastalarında 56,15±54,57 (p>0.05) sn bulunmuştur. Sol el testi PPMS hastalarında 39,64±16,71 sn, SPMS hastalarında 47,51±27,32 sn (p>0,05) bulunmuştur. Ortalama el testi PPMS hastalarında 36,25±11,83 sn, SPMS hastalarında 51,83±38,18 sn (p>0,05) bulunmuştur. Yürüme testi sadece tüm testleri yapabilen 39 hastada hesaplanmıştır. On dört PPMS hastasında birinci tur yürüme testi 35,62±22,2 sn, ikinci tur yürüme testi 36,21±24,73 sn, ortalama yürüme testi 35,92±22,81 sn bulunmuştur. Yirmi beş SPMS hastasında ise birinci tur yürüme testi 36,12±32,84 sn, ikinci tur yürüme testi 32,77±26,11 sn, ortalama yürüme testi 34,4±28,75 sn bulunmuştur (p>0.05). Sonuç: Genişletilmiş Özürlülük Durum Ölçeği skoru 5,1-6,0 arasındaki PPMS ve SPMS hastalarında EDSS ortalaması birbirine daha yakın olduğu ve bu gruptaki PPMS hastalarında üst ekstremite fonksiyonunu istatistiksel olarak anlamlı olmasa da göreceli olarak daha iyi olduğu görülmüştür. Alt ekstremite fonksiyonu açısından her iki grup arasında anlamlı fark bulunmamıştır.
Anahtar Kelimeler: Progresif MS hastalarında üst ve alt extremite fonksiyonu, 9-Hole PEG testi (9-HPT, Dokuz delikli çubuk testi) ve timed 25 Food Walk (25 adımlı yürüme testi,T25FW)
- Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210-8. [Crossref] [PubMed]
- Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J Neurol Sci. 2008;274(1-2):45-7. [Crossref] [PubMed]
- Vukusic S, Confavreux C. [Natural history of multiple sclerosis]. Presse Med. 2010;39(3): 359-62. [Crossref] [PubMed]
- Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606-16. [Crossref] [PubMed]
- Filippi M, Agosta F. Magnetic resonance techniques to quantify tissue damage, tissue repair, and functional cortical reorganization in multiple sclerosis. Prog Brain Res. 2009;175:465-82. [Crossref]
- Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999;53(8): 1698-704. [Crossref] [PubMed]
- Desrosiers J, Malouin F, Richards C, Bourbonnais D, Rochette A, Bravo G. Comparison of changes in upper and lower extremity impairments and disabilities after stroke. Int J Rehabil Res. 2003;26(2):109-16. [Crossref] [PubMed]
- Feys P, Lamers I, Francis G, Benedict R, Phillips G, LaRocca N, et al. The nine-hole peg test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017;23(5):711-20. [Crossref] [PubMed] [PMC]
- Larocca NG. Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient. 2011;4(3):189-201. [Crossref] [PubMed]
- Messick S. Validation of psychological assessment: Validation of inferences from persons' responses and performances as scientific inquiry into score meaning. Am Psychol. 1995;50:741-9. [Crossref]
- Motl RW. Ambulation and multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(2):325-36. [Crossref] [PubMed]
- Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010;74 Suppl 3:S8-15. [Crossref] [PubMed]
- Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977;44(2):367-73. [Crossref] [PubMed]
- Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and prediction. Neurology. 1991;41(5):685-91. [Crossref] [PubMed]
- Sumowski JF, Rocca MA, Leavitt VM, Riccitelli G, Comi G, DeLuca J, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you've got and how you use it. Neurology. 2013;80(24):2186-93. [Crossref] [PubMed] [PMC]
- Yozbatiran N, Baskurt F, Baskurt Z, Ozakbas S, Idiman E. Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients. J Neurol Sci. 2006;246(1-2):117-22. [Crossref] [PubMed]
- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-20. [Crossref] [PubMed]
- Tanigawa M, Stein J, Park J, Kosa P, Cortese I, Bielekova B, et al. Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis. Mult Scler J Exp Transl Clin. 2017 Jan 1. Doi: 10.1177/ 2055217316688930. [Crossref] [PubMed] [PMC]
- Ontaneda D, Cohen JA, Amato MP. Clinical outcome measures for progressive MS trials. Mult Scler. 2017;23(12):1627-35. [Crossref] [PubMed]
.: Process List